MX352595B - Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3'h-espiro[ciclohexano-1,1´pirano-[3,4,b ]indol]-4-amina y un componente de acido salicilico. - Google Patents

Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3'h-espiro[ciclohexano-1,1´pirano-[3,4,b ]indol]-4-amina y un componente de acido salicilico.

Info

Publication number
MX352595B
MX352595B MX2014012765A MX2014012765A MX352595B MX 352595 B MX352595 B MX 352595B MX 2014012765 A MX2014012765 A MX 2014012765A MX 2014012765 A MX2014012765 A MX 2014012765A MX 352595 B MX352595 B MX 352595B
Authority
MX
Mexico
Prior art keywords
salicylic acid
pyrano
indol
spiro
dihydro
Prior art date
Application number
MX2014012765A
Other languages
English (en)
Other versions
MX2014012765A (es
Inventor
Linz Klaus
Schiene Klaus
Frosch Stefanie
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2014012765A publication Critical patent/MX2014012765A/es
Publication of MX352595B publication Critical patent/MX352595B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se relaciona con una composición farmacéutica que comprende un primer ingrediente farmacológicamente activo seleccionado de (1R,4R)-6´-fluoro-N,N-dimetil-4-fenil-4´,9´-di-hid ro-3´H-espiro [ciclohexano-1,1´pirano-[3,4,b]indol]-4-amina y las sales fisiológicamente aceptables del mismo, y un segundo ingrediente farmacológicamete activo el cual es un componente de ácido salicílico seleccionado del grupo que consiste de ácido acetil salicílico, ácido salicílico, salicilaminda, etenzamida, salsato, dipirocetilo, benorilato, diflunisal, guacetisal, y las sales fisiológicamente aceptables de los mismos.
MX2014012765A 2012-05-18 2013-05-16 Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3'h-espiro[ciclohexano-1,1´pirano-[3,4,b ]indol]-4-amina y un componente de acido salicilico. MX352595B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12003936 2012-05-18
PCT/EP2013/001467 WO2013170968A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro [cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component

Publications (2)

Publication Number Publication Date
MX2014012765A MX2014012765A (es) 2014-11-21
MX352595B true MX352595B (es) 2017-11-30

Family

ID=48468207

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012765A MX352595B (es) 2012-05-18 2013-05-16 Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3'h-espiro[ciclohexano-1,1´pirano-[3,4,b ]indol]-4-amina y un componente de acido salicilico.

Country Status (23)

Country Link
US (1) US9855286B2 (es)
EP (1) EP2852386B1 (es)
JP (1) JP6116675B2 (es)
CN (1) CN104284661A (es)
AU (1) AU2013262074B2 (es)
BR (1) BR112014028564A2 (es)
CA (1) CA2873640A1 (es)
CY (1) CY1119692T1 (es)
DK (1) DK2852386T3 (es)
EA (1) EA026642B1 (es)
ES (1) ES2654146T3 (es)
HK (1) HK1204941A1 (es)
HR (1) HRP20171927T1 (es)
HU (1) HUE035930T2 (es)
IL (1) IL235656B (es)
LT (1) LT2852386T (es)
MX (1) MX352595B (es)
NO (1) NO2852386T3 (es)
PL (1) PL2852386T3 (es)
PT (1) PT2852386T (es)
RS (1) RS56674B1 (es)
SI (1) SI2852386T1 (es)
WO (1) WO2013170968A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022353B2 (en) 2015-01-23 2018-07-17 Grünenthal GmbH Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068838B1 (en) 1981-06-26 1986-09-17 The Upjohn Company Analgesic process and composition
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4404208A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
IE55189B1 (en) 1982-07-08 1990-06-20 Wyeth John & Brother Ltd Pharmaceutical compositions
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
ATE147731T1 (de) 1989-05-22 1997-02-15 Biochemical Veterinary Res Bivalente metallsalze von indomethacin
AU662160B2 (en) 1991-07-04 1995-08-24 Taisho Pharmaceutical Co., Ltd. Analgesic
US5339362A (en) 1992-01-07 1994-08-16 Rockford Corporation Automotive audio system
JPH05221857A (ja) 1992-02-14 1993-08-31 Arakusu:Kk 配合解熱鎮痛剤
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
CA2163995A1 (en) 1993-06-07 1994-12-22 Malcolm Maccoss Spiro-substituted azacycles as neurokinin antagonists
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
PT1109534E (pt) 1998-09-10 2003-06-30 Nycomed Danmark As Composicoes farmaceuticas de farmacos de libertacao rapida
ES2194536T3 (es) 1998-11-13 2003-11-16 Lilly Co Eli Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
EP1219304B1 (de) 2000-12-28 2004-10-20 Fresenius Kabi Austria GmbH Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
BR0307268A (pt) 2002-01-28 2004-12-14 Pfizer Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1
DE60219609T2 (de) 2002-06-17 2008-01-03 Chiesi Farmaceutici S.P.A. Prozess für die Vorbereitung von Piroxicam: Beta-Cyclodextrin Einschlusskomplexe
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10257824B4 (de) 2002-12-10 2004-11-11 Kochem, Hans-Günter, Dr. Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US7132452B2 (en) 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20080200490A1 (en) 2005-06-17 2008-08-21 Pfizer Inc. Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists
RU2465263C2 (ru) 2006-04-28 2012-10-27 Грюненталь Гмбх Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и нестероидный противовоспалительный препарат
SI2012764T1 (sl) 2006-04-28 2011-03-31 Gruenenthal Chemie Farmacevtska kombinacija, ki obsega 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in paracetamol
CN101147735A (zh) 2006-09-19 2008-03-26 沈阳华泰药物研究有限公司 注射用药物组合物及其药盒
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102006056458A1 (de) 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
ES2416723T3 (es) 2007-10-09 2013-08-02 Merck Patent Gmbh Composiciones farmacéuticas que contienen benfotiamina y gabapentina
CN100560061C (zh) 2008-06-20 2009-11-18 海南锦瑞制药股份有限公司 一种氯诺昔康冻干粉针剂及其制备方法
WO2010025931A2 (en) 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination
AR073277A1 (es) 2008-09-05 2010-10-28 Gruenenthal Gmbh Combinacion farmaceutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y paracetamol, y uso
KR20110065488A (ko) 2008-09-05 2011-06-15 그뤼넨탈 게엠베하 6-디메틸아미노메틸-1-(3-메톡시-페닐)-사이클로헥산-1,3-디올 및 ｎｓａｉｄ를 포함하는 약제학적 병용물
KR101882663B1 (ko) 2010-08-04 2018-07-30 그뤼넨탈 게엠베하 6’­플루오로­（Ｎ­메틸­ 또는 Ｎ，Ｎ­디메틸­）­4­페닐­4’，9’­디하이드로­3’Ｈ­스피로［사이클로헥산­1，1’­피라노［3，4，ｂ］인돌］­4­아민을 포함하는 약제학적 투여형
WO2012016703A2 (en) 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
RS58017B1 (sr) 2010-08-04 2019-02-28 Gruenenthal Gmbh Farmaceutska dozna forma koja sadrži 6'-fluoro-(n-metil- ili n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-amin za lečenje nociceptivnog bola
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
FR3010236B1 (fr) 2013-09-05 2017-01-13 Arkema France Additifs pour ameliorer la conductivite ionique des electrodes de batteries li-ion

Also Published As

Publication number Publication date
EA201401267A1 (ru) 2016-05-31
IL235656B (en) 2018-08-30
WO2013170968A1 (en) 2013-11-21
CN104284661A (zh) 2015-01-14
PL2852386T3 (pl) 2018-02-28
IL235656A0 (en) 2015-01-29
HUE035930T2 (hu) 2018-06-28
NO2852386T3 (es) 2018-04-14
CA2873640A1 (en) 2013-11-21
EP2852386A1 (en) 2015-04-01
LT2852386T (lt) 2018-01-10
JP2015516448A (ja) 2015-06-11
PT2852386T (pt) 2018-01-04
US9855286B2 (en) 2018-01-02
AU2013262074B2 (en) 2018-01-18
SI2852386T1 (en) 2018-04-30
JP6116675B2 (ja) 2017-04-19
US20130317076A1 (en) 2013-11-28
HK1204941A1 (en) 2015-12-11
RS56674B1 (sr) 2018-03-30
CY1119692T1 (el) 2018-04-04
AU2013262074A1 (en) 2015-01-22
HRP20171927T1 (hr) 2018-01-26
EP2852386B1 (en) 2017-11-15
MX2014012765A (es) 2014-11-21
EA026642B1 (ru) 2017-04-28
BR112014028564A2 (pt) 2017-06-27
DK2852386T3 (en) 2018-01-08
ES2654146T3 (es) 2018-02-12

Similar Documents

Publication Publication Date Title
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MX2013001677A (es) Formulaciones estables de linaclotida.
WO2010092090A3 (en) Novel salts of sitagliptin
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
EA201201109A1 (ru) Прасугрель в тонкоизмельченной кристаллической форме и фармацевтическая композиция, содержащая его
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
EP2722042A4 (en) INDANONE DERIVATIVES, THEIR OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2012131341A3 (en) Tight junctions modulators
MX2014001621A (es) Composiciones topicas antioxidantes.
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
MX356245B (es) Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3'h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un gabapentinoide.
MX352595B (es) Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3'h-espiro[ciclohexano-1,1´pirano-[3,4,b ]indol]-4-amina y un componente de acido salicilico.
EP2409685A3 (en) Orally-disintegrating formulations of prasugrel
WO2012169827A3 (ko) 속눈썹 성장용 조성물
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2012064306A3 (en) Effervescent formulations of rosuvastatin
WO2012047007A3 (ko) 손톱 또는 발톱 성장 촉진용 조성물
MX354684B (es) Composición farmacéutica que comprende (1r,4r)-6'-fluoro-n,n-dimet il-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b] indol]-4-amina y antidepresivos.
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate

Legal Events

Date Code Title Description
FG Grant or registration